Staar Surgical is a healthcare company specializing in the development and manufacturing of implantable lenses for vision correction. Its core products include the Visian ICL, a lens designed for patients with myopia and hyperopia. The company operates primarily in the ophthalmic surgical segment, focusing on innovative solutions for refractive vision correction. Major revenue sources stem from the sale of its lens products and related surgical services.
The investment profile of Staar Surgical is more aligned with growth investors, given its focus on innovation and market expansion in the ophthalmic sector. The company does not currently offer dividends, making it less suitable for income-focused investors. The stock may appeal to those looking for potential capital appreciation over a medium to long-term horizon, considering its growth-oriented strategy.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-11-08 | Hold | Sell | Weak fundamentals and negative momentum raise significant concerns. |
| 2026-10-29 | Sell | Hold | Weak fundamentals and high risk limit upside potential. |
| 2026-10-07 | Hold | Sell | Weak fundamentals and negative momentum signal high risk. |
| 2026-09-30 | — | Hold | Mixed performance; high risk with uncertain fundamentals. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-11-05 | UBS | Target Raised | — → 34 | 27.17 |
| 2026-09-29 | Veritas Investment Research | Update | — → 31 | 20.87 |
| 2026-09-22 | Jefferies | Target Lowered | 28 → 23 | 20.19 |
| 2026-08-17 | UBS | Target Lowered | — → 28 | 26.18 |
| 2026-08-13 | Jefferies | Target Lowered | — → 28 | 25.33 |
| 2026-08-13 | William Blair | Update | — → 33 | 24.96 |
| 2026-08-13 | UBS | Target Lowered | 20 → 19 | 24.83 |
| 2026-05-14 | Mizuho Securities | Target Raised | 22 → 27 | 29.4 |
| 2026-05-14 | Canaccord Genuity | Target Raised | 27 → 32 | 29.4 |
| 2026-05-14 | Wedbush | Rating Upgraded | — → 40 | 29.4 |
| 2026-05-14 | Piper Sandler | Target Raised | 16 → 33 | 29.4 |
